Phaseline

Companies › BioLab Holdings

BioLab Holdings: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 4; Metabolic and endocrine; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Membrane Wrap-Hydro™
Human placental membrane product
–Phase 4Diabetic FootJul 2027
Membrane Wrap-Lite™
Human placental membrane product
–Phase 4Diabetic FootJul 2027
Membrane Wrap™
Human placental membrane product
–Phase 4Diabetic FootJul 2027
Tri-Membrane Wrap™
Human placental membrane product
–Phase 4Diabetic FootJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07089602Tri-Membrane Wrap™Phase 4Diabetic FootMetabolic and endocrineJul 2027
NCT07089602Membrane Wrap™Phase 4Diabetic FootMetabolic and endocrineJul 2027
NCT07089602Membrane Wrap-Lite™Phase 4Diabetic FootMetabolic and endocrineJul 2027
NCT07089602Membrane Wrap-Hydro™Phase 4Diabetic FootMetabolic and endocrineJul 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Yong Zhao, MD, PhD Applied Biologics Spur Therapeutics iECURE Sequence LifeScience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.